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Abstract
Changes in lipid metabolism and iron content are observed in the livers of patients with fatty
liver disease. The expression of hepcidin, an iron-regulatory and acute phase protein syn-
thesized by the liver, is also modulated. The potential interaction of lipid and iron metabo-
lism is largely unknown. We investigated the role of lipid intermediate, ceramide in the
regulation of human hepcidin gene, HAMP. Human hepatoma HepG2 cells were treated
with cell-permeable ceramide analogs. Ceramide induced significant up-regulation of
HAMPmRNA expression in HepG2 cells. The effect of ceramide on HAMP expression
was mediated through transcriptional mechanisms because it was completely blocked with
actinomycin D treatment. Reporter assays also confirmed the activation of 0.6 kb HAMP
promoter by ceramide. HepG2 cells treated with ceramide displayed increased phosphory-
lation of STAT3, JNK, and NF-κB proteins. However, ceramide induced the binding of
STAT3, but not NF-κB or c-Jun, to HAMP promoter, as shown by the chromatin immunopre-
cipitation assays. The mutation of STAT3 response element within 0.6 kb HAMP promoter
region significantly inhibited the stimulatory effect of ceramide on HAMP promoter activity.
Similarly, the inhibition of STAT3 with a pan-JAK kinase inhibitor and STAT3 siRNA pool
also diminished the induction of both HAMP promoter activity and mRNA expression by cer-
amide. In conclusion, we have shown a direct role for ceramide in the activation of hepatic
HAMP transcription via STAT3. Our findings suggest a crosstalk between lipid and iron
metabolism in the liver, which may contribute to the pathogenesis of obesity-related fatty
liver disease.
Introduction
More than one third of the US adult population is estimated to have non-alcoholic fatty liver
disease (NAFLD) [1] and its prevalence is further expanding to both developing countries and
children [2]. NAFLD, by definition, is the accumulation of fat (steatosis) in the livers of patients
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with no or little alcohol consumption [3]. Inflammation (steatohepatitis) and iron are impor-
tant secondary risk factors for the progression of NAFLD to non-alcoholic steatohepatitis
(NASH), which can eventually lead to cirrhosis and hepatocellular carcinoma [4–7]. NAFLD/
NASH patients frequently display elevated levels of serum iron indices and hepatic iron con-
tent [8,9]. The deposition of iron in the liver correlates with disease severity and the develop-
ment of fibrosis [10–12].
The discovery of hepcidin was instrumental in understanding the connection between
inflammation and iron homeostasis [13–16]. Hepcidin, mainly synthesized in the hepatocytes
of the liver, is both an acute phase protein and a pivotal regulator of iron metabolism [13–16].
Hepcidin controls systemic iron homeostasis by inhibiting the function of iron exporter ferro-
portin [17]. As an acute phase protein, hepcidin responds to inflammation. Hepcidin expres-
sion is hence regulated by the inflammatory cytokines, IL-1 and IL-6. The transcription of
hepcidin gene, HAMP has been shown to be activated by the binding of the transcription fac-
tor, STAT3 toHAMP promoter [14,15,18]. STAT3 is regulated by Janus kinases (JAK) via
phosphorylation of a conserved tyrosine residue near the C-terminus [19].
Several factors including increased gut permeability, adipose tissue-derived cytokines and
adipokines, Kupffer cell activation, and lipid accumulation induce inflammation in the livers of
NAFLD patients [7,20]. Hepcidin expression is modulated in NAFLD patients [12,21,22] but
the underlying mechanisms are unclear. In overly obese patients undergoing bariatric surgery,
a relationship between adipose tissue-derived IL-6, and elevated hepcidin expression in adipose
tissue has been shown [22].
Fat accumulation and inflammation in the livers of NAFLD patients stimulate the synthesis
of the sphingolipid, ceramide through de novo and sphingomyelinase pathways [23,24].
Accordingly, elevated hepatic fat content is associated with increased ceramide levels in obese
individuals [25] while weight loss is correlated with reduced pro-ceramide gene expression,
decreased serum ceramide levels, and the reversal of NASH pathogenesis in the liver [26]. Ani-
mal studies have also demonstrated that high fat intake increases ceramide production in the
liver [27] and the inhibition of ceramide synthesis reduces hepatic steatosis and improves insu-
lin signaling [28,29]. The mechanisms by which ceramide participates in the pathogenesis of
NAFLD and the regulation of HAMP expression is unknown.
Although initially regarded simply as a structural component of biomembranes, ceramide
has recently been recognized as a signaling molecule [24]. Besides its negative effect on insulin
signaling [30], ceramide also activates inflammatory signaling pathways. Both the tyrosine
phosphorylation and DNA-binding activity of the transcription factor, STAT3 has been shown
to be stimulated by ceramide in a JAK-dependent manner in cultured fibroblast cells [31]. Cer-
amide has also been reported to activate the transcription factor, NF-κB and its down-steam
targets in HepG2 and other cells [32–34]. A role for c-Jun N-terminal kinase (JNK) has been
shown both in inflammation and steatosis in NAFLD [35]. The absence of JNK1 expression in
a knockout mouse model has been shown to inhibit steatohepatitis induced by methionine-
choline deficient diet intake [36]. Upon phosphorylation and activation, JNK in turn phos-
phorylates serine residues in the N-terminal of c-Jun and thereby up-regulates its capability to
trans-activate genes harboring AP-1 enhancer sequences in the promoter region [37]. Cer-
amide has also been reported to stimulate JNK activation [38–40]. Despite being regulated by
metabolic changes and inflammation, and its direct participation in inflammatory signaling,
the effect of ceramide on hepatic HAMP expression is unknown. In the current study, we
investigated the mechanisms underlyingHAMP regulation by ceramide in human hepatoma
cells.
HepaticHAMP Transcription Is Stimulated by Ceramide via STAT3
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Materials and Methods
Reagents
Synthetic cell-permeable ceramide analogs, C2 (#62525), and C6 (#62510) ceramide, and pan-
JAK kinase inhibitor, JAK inhibitor I (#15146) were purchased from Cayman Chemical. JNK
inhibitor, SP600125 was purchased from Enzo Life Sciences. siGENOME Human STAT3
siRNA SMART pool and control siRNA were obtained from Dharmacon.
Cell culture
HepG2 human hepatoma cells, obtained from the American Type Culture Collection (ATCC),
were maintained in high glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with glutamine and 10% fetal calf serum (Atlantic Biologicals). 1.3×106 or 3.9 ×106 cells were
seeded in 25 cm2 or 75 cm2 flasks, respectively overnight prior to experiments. Cells were
treated with ceramide analogs or solvent (0.1% DMSO), as control, for 8 hours. All inhibitors
were added 1 hour prior to treatments with ceramide or DMSO.
Transfections
Lipofectamine 3000 (Life Technologies) was employed for the transfection of plasmids for dual
luciferase assays. RNAiMax (Life Technologies) was used for the transfection of siRNAs. The
transfections were performed, as recommended by the manufacturers. For siRNA experiments,
two consecutive transfections, 24 hours apart, were performed.
RNA Isolation, cDNA Synthesis, and Real-Time Quantitative PCR
Analysis
RNA was isolated with Trizol reagent (Life Technologies), as described by the supplier. Super-
Script II Reverse Transcriptase (Life Technologies) and random hexamers (Applied Biosys-
tems) were used for cDNA synthesis. qPCR assays using Taqman probe and primers were
performed, as described previously [41].
XBP1-splicing assay
X-box binding protein 1 (XBP1) splicing assay is based on the fact that spliced form of XBP1
mRNA lacks the recognition sequence for Pst1 enzyme, which is present in the unspliced form
[42]. In brief, PCR was performed using cDNA, synthesized from HepG2 cell RNA, and a
XBP1 specific primer pair: (forward: 5’-AAACAGAGTAGCAGCTCAGACTGC-3’, reverse:
5’-TCCTTCTGGGTAGACCTCTGGGAG-3’). The amplicons 448 bp and 474 bp, which indi-
cate spliced and unspliced forms of XBP1, respectively were subsequently digested with Pst I at
37°C for 2 hours. Following digestion, unspliced XBP1 amplicon (474 bp) yielded 290 bp and
183 bp fragments. The digested products were subjected to DNA agarose gel electrophoresis.
GAPDH, used as the loading control, was amplified with the following primer pair: (forward:
5’- TGGTATCGTGGAAGGACTC-3’, reverse: 5’- AGTAGAGGCAGGGATGATG-3’).
Cell lysis and western blotting
Cells were lysed with phopho-lysis buffer [10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM
EDTA and 10% glycerol] supplemented with 1 mM PMSF, 0.5% Triton X-100, protease inhibi-
tor cocktail, pepstatin A (Sigma-Aldrich), phosphatase inhibitor cocktail (Sigma), and activated
sodium orthovanadate (Acros Organics). Three rounds of 5 sec. sonications at 50% amplitude
with ultrasonic dismembrator 150T (Fisher Scientific) were performed to facilitate cell lysis.
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After removing cell debris by centrifugation (3000 x g for 5 min.), supernatants were used for
western blotting.
Western blotting was performed, as described previously [41]. Primary antibodies, anti-
Phospho-STAT3 (Tyr 705) (Cell signaling #9131), anti-STAT3 (#9132), anti-Phospho-JNK
(#9251), anti-JNK (9252), anti-Phospho-NF-κB p65 (#3033), anti-NF-κB p65 (#4764),
anti-GRP78 (Santa Cruz, # SC-166490), anti-CHOP (#SC-7351), anti-gapdh (Millipore,
#MAB374), and secondary anti-mouse or anti-rabbit antibodies (Cell signaling) were obtained
commercially. Immune-reactive bands were detected by the ImmunStar-AP Substrate (Bio-
Rad Laboratories).
Plasmid DNA constructs, mutagenesis and dual luciferase reporter
assays
For cloning, the 0.6 kbHAMP promoter region (+36 to -593) was amplified by PCR using Phu-
sion High-Fidelity DNA Polymerase (Thermo Scientific) and specific primers [(Forward
primer with MluI site: 5’- GGACGCGTTGTCATTTATGGCCAAAAGTTTGCT-3’) (Reverse
primer with XhoI site: 5’- GACTCGAGTGAGCTTGCTCTGGTGTCTG-3’)]. Amplified and
purified PCR product was digested with the corresponding restriction enzymes, and inserted
into pGL3-Basic Luciferase Vector (Promega). The ligated plasmid was electroporated into
electro-competent DH5α bacterial cells with MicroPulse electroporator system (Bio-Rad). The
transformed bacteria were selected on LB Agar plates containing Ampicillin. Single colonies
were picked and cultured for plasmid purification with a commercial miniPrep kit (Qiagen).
The insert sequences of recombinant plasmids were verified by DNA sequencing. For transfec-
tions, plasmids purified by a MaxiPrep kit (Qiagen) were used.
Mutation of the consensus STAT3 DNA-binding site on the 0.6 kbHAMP promoter region
was performed with Quickchange II Site-Directed Mutagenesis kit (Agilent Technologies)
using specific primers: (forward: 5'-CTGTCTCATTTCCAGGTGGTGGCGCCGAAAA-3'
reverse: 5'-TTTTCGGCGCCACCACCTGGAAATGAGACAG-3'), as described by the
manufacturer.
HepG2 cells were transfected with either empty pGL-3 Basic vector (as control) or recombi-
nant reporter vector, as described. pRL-SV40 plasmid was co-transfected as a reference for
transfection efficiency. Dual luciferase reporter assays were performed according to the manu-
facturer’s guidelines (Promega).
Promoter analysis and chromatin immunoprecipitation (ChIP) assays
The presence of consensus DNA-binding sites for transcription factors, STAT3 and AP-1
within the 0.6 kbHAMP promoter region have previously been identified [43,44]. We have
identified a putative NF-κB (subunit P65) binding site on 0.6kbp HAMP promoter (-583bp to
-592bp from ATG) by using MatInspector [45]. ChIP assays were performed, as described pre-
viously [46]. Briefly, 50 x106 HepG2 cells were fixed with 1% formaldehyde for 10 min. at
room temperature. The cross-linking was stopped with 0.1375M glycine solution. Cells,
washed twice with cold 1xPBS, were subsequently lysed with ChIP lysis buffer [5 mM PIPES
(pH 8.0), 85 mM KCl, 0.5% Nonidet P-40 (NP-40)] supplemented with protease inhibitors.
Nuclei fractions collected by centrifugation at 1000 x g for 10 minutes at 4°C, were lysed on ice
for 10 minutes with a lysis buffer [50 mM Tris-Cl (pH 8.0), 10 mM EDTA, 1% SDS, protease
inhibitors]. The lysates were then sonicated using ultrasonic dismembrator 150T (Fisher Scien-
tific) with the following settings: (50% amplitude, 6 x 30 sec. cycles). 100 μg of chromatin was
pre-cleared for 2 hours at 4°C with 50 μl protein A-Agarose beads (Santa Cruz) blocked with
Herring Sperm DNA (Promega). 5 μl of the pre-cleared chromatin was saved as input control.
HepaticHAMP Transcription Is Stimulated by Ceramide via STAT3
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The pre-cleared chromatin was then incubated overnight at 4°C with anti-STAT3 (Cell signal-
ing, #9132), anti-NF-κB p65 (#4764), anti-c-Jun (Santa Cruz, #sc-45) antibodies or normal
rabbit/mouse IgG (Santa Cruz), as a negative control. The next day, chromatin and IgG com-
plexes were captured by incubating with 50 μl of blocked protein A-Agarose beads for 2 hours
at 4°C. Immunoprecipitates were subjected to sequential washes as follows: (1x with low salt
buffer [20 mM Tris/HCl (pH 8.0), 2 mM EDTA, 150 mMNaCl, 0.1% SDS and 1% Triton X-
100], 1 X with high salt buffer [20 mM Tris/HCl (pH 8.0), 2 mM EDTA, 500 mMNaCl, 0.1%
SDS and 1% Triton X-100] and 1 X with lithium chloride wash buffer [10 mM Tris/HCl (pH
8.0), 1 mM EDTA, 250 mM LiCl, 1% Triton X-100, 1% Igepal and 1% deoxycholic acid], and
3x with 1x TE buffer. Washed chromatin was subsequently eluted using a freshly-prepared elu-
tion buffer (100 mMNaHCO3 and 1% SDS), and reverse cross-linked with 200 mMNaCl at
65°C overnight. The next day, samples were treated with DNase-free RNase and proteinase K
(Fisher Scientific), and purified using a commercial Qiaquick PCR purification kit (Qiagen).
HAMP promoter was amplified by PCR using specific primers designed with Primer-BLAST
(NCBI), as listed in Table 1.
Statistical Analysis
The significance of difference between groups was determined by Student’s t-test or one-way
ANOVA with Tukey's HSD post-hoc test by using SPSS software. A value of P< 0.05 was
accepted as statistically significant.
Results
In order to study the role of ceramide in the regulation of HAMP expression, human hepatoma
HepG2 cells were treated with synthetic cell-permeable ceramide analogs, C2 and C6 ceramide.
These analogs are commonly used to study the effects of ceramide in different experimental
systems [23,39,47]. We chose 30 μM and 60 μM ceramide analog concentrations because they
are widely used in other studies [33,48] and our preliminary studies have also shown that cells
treated with these concentrations for 8 hours exhibit over 90% cell viability. Similar ceramide
concentrations have also been detected in the plasma of human NAFLD patients [27] and in
lipid-infused rats [49]. We treated control cells with solvent (0.1% DMSO).
The effect of ceramide analogs on hepcidin expression was determined by measuring the
level ofHAMPmRNA by qPCR, as described in the experimental procedures. HepG2 cells
treated with 30 μM or 60 μM of C2 ceramide displayed an 1.78 ± 0.35 and 3.43 ± 0.39 -fold
increase inHAMP expression, respectively, compared to control cells treated with solvent (Fig
1A). Both C2 and C6 ceramide analogs significantly elevated HAMPmRNA expression (Fig
1A). Since, C2 exerted a more potent effect than C6 under similar experimental conditions, we
employed C2 ceramide analog for further experiments.
Studies to this date have shown thatHAMP expression is regulated via transcription [44,50–
52]. To determine whether ceramide also regulated HAMP at the transcriptional level, we
employed the transcription inhibitor, actinomycin D. For these experiments, HepG2 cells were
treated with ceramide or solvent in the presence of either actinomycin D or DMSO, as control.
Table 1. The sequence of primers used for ChIP assays.
Gene Forward Primer Reverse Primer
STAT3 GAGGGTGACACAACCCTGTT ACCGAGTGACAGTCGCTTTT
NF-κB TCATTTATGGCCAAAAGTTTGCT CAAGCATCAGCGTGTGCC
c-Jun TGAGGGTGACACAACCCTGT CTGCTGGGTCTTGAGCTTGC
doi:10.1371/journal.pone.0147474.t001
HepaticHAMP Transcription Is Stimulated by Ceramide via STAT3
PLOSONE | DOI:10.1371/journal.pone.0147474 January 25, 2016 5 / 18
Fig 1. Ceramide analogs inducedHAMP transcription. (A) HAMPmRNA expression in HepG2 cells,
treated with 30 μM or 60 μM of C2 and C6 ceramide or solvent (solv.) control for 8 hours, was determined by
Taqman qPCR, as described in experimental procedures. HAMPmRNA levels in ceramide-treated cells was
expressed as fold change of that in solvent-treated cells. (B) HepG2 cells were treated with 60 μMC2
ceramide or solvent in the presence of either 1μg/ml actinomycin D (ACTD) or DMSO as control.HAMP
mRNA expression, determined by qPCR, in treated cells was calculated as fold change of that in control cells,
incubated with solvent and DMSO. (C) The effect of ACTD onHAMP up-regulation induced by ceramide was
shown by calculatingHAMP expression in C2 ceramide-treated cells as fold change of that in cells treated
with solvent. (D) HepG2 cells, transfected with pGL-3 basic vector harboring 0.6kbpHAMP promoter (HAMP-
Prom-Luc) or empty pGL-3 basic vector (vector), and pRL-SV40 plasmid as control for transfection efficiency,
HepaticHAMP Transcription Is Stimulated by Ceramide via STAT3
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The addition of DMSO did not alter C2 ceramide-mediated induction of HAMPmRNA
expression (Fig 1B). Actinomycin D by itself significantly decreased the level of HAMPmRNA
in HepG2 cells (Fig 1B), Simultaneous treatment of HepG2 cells with actinomycin D and cer-
amide completely blocked ceramide-induced HAMPmRNA up-regulation (Fig 1B and 1C).
To further confirm the involvement of transcriptional mechanisms in HAMP regulation by
ceramide, reporter assays were performed using a 0.6 kb region ofHAMP promoter, which
harbors binding sites for various transcription factors [43,52] (Fig 1D). HepG2 cells, trans-
fected with either empty pGL-3 basic vector or vector containing 0.6kbHAMP promoter
(HAMP-Prom-Luc), were co-transfected with pRL-SV40 plasmid encoding renila luciferase as
a reference for transfection efficiency, as described in experimental procedures. A significantly
higher level of luciferase activity was detected in cells transfected with the vector harboring
HAMP promoter compared to cells transfected with the empty pGL-3 basic vector (Fig 1D).
Ceramide treatment further increased reporter activity in HepG2 cells transfected with
HAMP-Prom-Luc, but not with empty vector (Fig 1D). Both actinomycin D and reporter
assay studies have shown that ceramide activates HAMP transcription in HepG2 cells, and that
this activation is conveyed through cis-elements contained within the 0.6 kb HAMP promoter
region.
Ceramide treatment has been reported to induce the activation of various inflammatory sig-
naling pathways including JAK/STAT3, NF-κB and JNK/c-Jun in vitro [31–34,38–40]. How-
ever, its signaling effect in hepatoma cells is largely unknown. Therefore, western blots were
performed using specific anti-phospho antibodies to examine the activating status of these sig-
naling molecules (Fig 2A and 2B). STAT3 is phosphorylated on tyrosine (Tyr 705) residue by
JAK kinases for activation [53]. Ceramide significantly stimulated the tyrosine phosphorylation
of STAT3 in HepG2 cells (Fig 2A). HepG2 cells treated with recombinant IL-6, as a positive
control, also displayed STAT3 phosphorylation at tyrosine 705, confirming the specificity and
sensitivity of our antibody and western blotting assays (Fig 2A). The expression level of total
STAT3 protein in HepG2 cells was not altered by ceramide or IL-6 (Fig 2A). Similar to STAT3,
ceramide also stimulated the phosphorylation of NF-κB subunit P65 and JNK (Fig 2B) in
HepG2 cells.
In order to determine the role of ceramide-induced signaling pathways in HAMP transcrip-
tional activation, various experiments were performed. Chromatin immunoprecipitation
(ChIP) assays were utilized to identify the transcription factors physically interacting with
HAMP promoter in ceramide-treated HepG2 cells (Fig 3A and 3B). Specific commercial anti-
bodies validated for ChIP assay were employed to detect the binding of transcription factors,
STAT3, NF-κB and c-Jun toHAMP promoter. Same concentrations of normal rabbit or mouse
IgG were used as negative controls. The primers used for ChIP analysis (Table 1) amplified
HAMP promoter regions, which harbored consensus sites for respective transcription factors
(STAT3: -135bp to -143bp; AP-1: -126bp to -134bp; NF-κB P65: -583bp to -592bp proximal to
the start codon, ATG). ChIP assay results indicated that ceramide significantly increased the
binding of STAT3 to HAMP promoter, compared to solvent treatment in HepG2 cells (Fig
3A). As a positive control, HepG2 cells were treated with the cytokine, IL-6, a well-character-
ized inducer of HAMP transcription through STAT3 activation [15]. IL-6 stimulated the bind-
ing of STAT3 to HAMP promoter, which validated our ChIP assay system (Fig 3B). Unlike
were treated with 60 μMC2 ceramide or solvent for 8 hours. Dual luciferase report assays were performed,
as described in the experimental procedures. HAMP promoter activity, expressed in relative luciferase units,
was calculated as fold change of that in cells transfected with the empty vector and treated with solvent.
Asterisks indicate statistical significance (P<0.05).
doi:10.1371/journal.pone.0147474.g001
HepaticHAMP Transcription Is Stimulated by Ceramide via STAT3
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STAT3, ceramide did not activate the binding of NF-κB p65 subunit toHAMP promoter (Fig
3A). In contrast, the binding of c-Jun, a classical transcription factor activated by JNK, toHAMP
promoter was weaker in ceramide-treated HepG2 cells compared to that in solvent-treated cells
(Fig 3A). Our ChIP results were specific because no significant immune precipitation was
observed with control IgG samples in any of our ChIP assays (representative images are shown
in Fig 3A and 3B). Furthermore, equal amount of chromatin was used across the samples in our
ChIP assays, as shown by the total amount of chromatin input (Fig 3A and 3B).
Fig 2. The effect of ceramide on the phosphorylation of STAT3, JNK and NF-κB in HepG2 cells. Protein
lysates isolated from HepG2 cells treated with 60 μMC2 ceramide or solvent control, and 40 ng/ ml
recombinant IL-6 or PBS control for 8 hours, were employed for western blotting to determine the level of total
or phosphorylated proteins. Total STAT3 (T-STAT3) or STAT3 phosphorylated on tyrosine 705 (P-STAT3)
(A), total (T-P65) or phosphorylated (P-P65) NF-κB subunit P65, and total (T-JNK) or phosphorylated-JNK
(P-JNK) (B) protein levels were determined by using specific antibodies. An anti-gapdh antibody was
employed as a protein loading control.
doi:10.1371/journal.pone.0147474.g002
HepaticHAMP Transcription Is Stimulated by Ceramide via STAT3
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To validate the direct involvement of STAT3 in ceramide-mediated transcriptional regula-
tion ofHAMP, the STAT3 response element in the 0.6kbp HAMP promoter reporter construct
was mutated, as described in the experimental procedures. Luciferase reporter assays were then
performed with pGL-3 basic vectors harboring the wild-type or mutated HAMP promoter (Fig
4A). Mutation of the STAT3 response element (ΔSTAT3) significantly diminished the
Fig 3. Ceramide stimulated the binding of STAT3, but not NF-κB subunit P65 or c-Jun, toHAMP
promoter. (A) Chromatin, isolated from HepG2 cells treated with 60 μMC2 ceramide or solvent (solv.) for 8
hours and fixed with 1% formaldehyde, was incubated with antibodies specific for STAT3, NF-κB subunit P65
or c-Jun for chromatin immunoprecipitation (ChIP) assays, as described in the experimental procedures.
Normal rabbit or mouse IgG were employed as negative controls. Immunoprecipitated and purified chromatin
and total input chromatin (loading control) were used for PCR to amplify a HAMP promoter region harboring
corresponding consensus sequences by using specific primers. Representative images of amplicons,
analyzed by DNA agarose gel electrophoresis, visualized by ethidium bromide staining, and captured using
Gel Doc XR+ system (Bio-Rad), are shown. (B) ChIP assays were performed with HepG2 cells treated with
recombinant IL-6 or PBS (control) by using anti-STAT3 antibodies, as described above.
doi:10.1371/journal.pone.0147474.g003
HepaticHAMP Transcription Is Stimulated by Ceramide via STAT3
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stimulatory effect of ceramide on HAMP promoter, confirming the direct involvement of
STAT3 (Fig 4A). We validated the mutated promoter construct with IL-6 treatment because
this STAT3 response element is required for IL-6-responsiveness of HAMP promoter [15,44].
Accordingly, the mutation of STAT3 response element (ΔSTAT3) abolished IL-6-induced
HAMP promoter activation (Fig 4B).
In order to study the involvement of JAK/STAT3 signaling in the transcriptional regulation
ofHAMP expression induced by ceramide, STAT3 siRNA and a chemical pan-JAK kinase
inhibitor, JAK inhibitor I were employed (S1A and S1B Fig). The specificity of STAT3 siRNA
was confirmed by real-time PCR and western blotting. The levels of STAT3 mRNA (S1A Fig)
and protein (S1A Fig inset) expression were significantly inhibited by STAT3 siRNA as com-
pared to control siRNA-transfected HepG2 cells. JAK inhibitor I treatment significantly inhib-
ited ceramide-induced phosphorylation of STAT3 at residue Tyr 705 under our experimental
conditions, as confirmed by western blotting (S1B Fig).
Fig 4. The effect of STAT3 response element mutation onHAMP promoter activation by ceramide. The
single STAT3 response element within 0.6kbpHAMP promoter region cloned in pGL3 basic vector was
mutated, as described in the experimental procedures. HepG2 cells, transfected with pGL3-basic vector
harboring wild-type (WT) or mutated (ΔSTAT3) 0.6 kb HAMP promoter, or empty vector (vector) as negative
control, and pRL-SV40 plasmid, as control for transfection efficiency, were treated with (A) 60 μMC2
ceramide (C2) and solvent control (solv.) or (B) 40 ng/ ml IL-6 and PBS control for 8 hours. Dual luciferase
reporter assays were performed, as described in the experimental procedures. HAMP promoter activity,
expressed in relative luciferase units, in treated cells was calculated as fold change of that in control cells
transfected with empty vector-and treated with solvent. Asterisks indicate statistical significance (P<0.05).
doi:10.1371/journal.pone.0147474.g004
HepaticHAMP Transcription Is Stimulated by Ceramide via STAT3
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The effect of JAK inhibitor I on the regulation of HAMPmRNA expression by ceramide
was determined by qPCR (Fig 5A). The addition of DMSO, which is the vehicle for JAK inhibi-
tor I did not affect ceramide-induced HAMP up-regulation (3.44 ± 0.41 fold). In comparison,
ceramide-mediated induction of HAMP expression was significantly attenuated by JAK inhibi-
tor I (2.28 ± 0.23 fold) (Fig 5A). Since the inhibition was incomplete, HepG2 cells were further
pre-treated with both STAT3 siRNA and JAK inhibitor I. Control cells were administered with
control siRNA and DMSO in parallel. Both groups of pre-treated cells were then subjected to
either ceramide or DMSO (control) treatment andHAMPmRNA expression was determined
(Fig 5B). Control siRNA and DMSO pre-treatment did not alter the effect of ceramide on
HAMPmRNA expression levels (3.15 ± 0.05 fold increase Fig 5B). By contrast, the combined
Fig 5. Activation of STAT3 signaling was required for the induction of HAMP transcription by ceramide (A) HAMPmRNA expression in HepG2 cells,
treated with solvent (solv.) or C2 ceramide for 8 hours in the presence of either 5 μM JAK inhibitor I or DMSO (control), was determined by Taqman qPCR.
HAMP expression in treated cells was calculated as fold change of that in respective control cells treated with solvent. (B) HepG2 cells, pre-transfected with
STAT3 or control siRNA, were treated with C2 ceramide or solvent (solv.) in the presence of 5 μM JAK inhibitor I or DMSO. HAMPmRNA levels, determined
by qPCR, were expressed as fold expression of that in respective controls treated with solvent. (C) HepG2 cells, transfected with pGL3-basic vector
harboring 0.6 kb HAMP promoter, were treated with C2 ceramide or solvent (solv.) for 8 hours in the presence or absence of 5 μM JAK inhibitor I. Dual
luciferase assays were performed and HAMP promoter activity, calculated as fold change of that in corresponding control cells treated with solvent, was
expressed in relative luciferase units. (D) HepG2 cells, pre-transfected with STAT3 or control siRNA, were subsequently transfected with pGL3-basic vector
harboring 0.6 kb wild-type HAMP promoter. After treatment with solvent (solv.) and C2 ceramide in the presence of either JAK inhibitor I or DMSO, dual
luciferase reporter assays were performed. HAMP promoter activity, expressed as relative luciferase units, was expressed as fold change of that in
respective control cells treated with solvent. Asterisks indicate statistical significance (P<0.05).
doi:10.1371/journal.pone.0147474.g005
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pre-treatment with STAT3 siRNA and JAK inhibitor I decreased the induction ofHAMP
mRNA expression by ceramide (1.57 ± 0.09 fold increase Fig 5B). The effect of JAK inhibitor I
and STAT3 siRNA on ceramide-induced HAMP promoter activation was further examined
with luciferase reporter assays (Fig 5C and 5D). HepG2 cells, transfected with pGL-3 basic vec-
tor harboring 0.6 kbpHAMP promoter, were treated with ceramide or solvent in the presence
of either JAK inhibitor I or DMSO as control. Ceramide treatment induced a 2.16 ± 0.32 fold
increase inHAMP promoter activity, as compared to control cells treated with solvent in the
presence of DMSO. In contrast to DMSO, the addition of JAK inhibitor I significantly dimin-
ished ceramide-induced HAMP promoter activation (1.69 ± 0.21 fold) (Fig 5C). The level of
inhibition was stronger with the combined pre-treatment of STAT3 siRNA and JAK inhibitor I
(1.39 ± 0.10 fold) (Fig 5D). HepG2 cells pre-treated with control siRNA and DMSO displayed
2.22 ± 0.36 fold increase inHAMP promoter activity following ceramide treatment (Fig 5D).
The mutation of STAT3 response element or the inhibition of STAT3 did not completely
eliminate the stimulatory effect of ceramide on HAMP promoter activity and mRNA expres-
sion. The residual activation may be facilitated by other signaling pathways stimulated by cer-
amide. We therefore examined the involvement of JNK and ER stress, which are activated by
ceramide. To study the effect of ceramide-induced JNK activation on HAMP expression, we
employed SP600125 a specific chemical inhibitor of JNK activation [54]. HepG2 cells were
treated with ceramide in the presence of SP600125 or DMSO, as control. The inhibition of cer-
amide-induced JNK phosphorylation by SP600125 was confirmed by western blotting using
anti-phospho-JNK antibodies (Fig 6A). DMSO did not exert any specific effect on JNK phos-
phorylation (Fig 6A). Ceramide-induced phosphorylation of JNK was significantly blocked by
SP600125 treatment under our experimental conditions (Fig 6A). The effect of SP600125 on
ceramide-mediated increase inHAMPmRNA expression levels was examined by qPCR.
Despite inhibiting JNK phosphorylation, SP600125 did not interfere with the induction of
HAMPmRNA by ceramide treatment in HepG2 cells (Fig 6B). These results exclude a role of
JNK in the up-regulation of HAMP expression by ceramide.
Ceramide has been shown to trigger ER stress in neuronal cells and various cancer cell lines
[55–57] but not in HepG2 cells. Independent studies have also reported activation of hepatic
HAMP transcription by ER stress [58]. We determined the effect of ceramide on ER stress in
Fig 6. Ceramide-inducedHAMP up-regulation was not dependent on c-Jun N-terminal kinase (JNK) phosphorylation. HepG2 cells treated with
ceramide or solvent in the presence of 50 μM chemical JNK inhibitor, Sp600125 or DMSO (control) were used to isolate protein (A) for western blotting to
determine phosphorylated (P-JNK) and total JNK protein (T-JNK) levels using specific antibodies or to isolate RNA (B) to determineHAMPmRNA
expression by Taqman qPCR. HAMP expression in ceramide-treated cells was calculated as fold expression of that in respective control cells treated with
solvent. Asterisks indicate statistical significance (P<0.05).
doi:10.1371/journal.pone.0147474.g006
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HepG2 cells by XBP1-splicing assay, as described in experimental procedures. Spliced form of
XBP1 was employed as an ER stress marker because ER stress-activated inositol-requiring
enzyme 1 (IRE1) is known to splice X-box binding protein 1 (XBP1) mRNA [59]. Tunicamy-
cin, a well-known chemical ER stress inducer [60], was also used as a positive control. Tunica-
mycin significantly increased the spliced and decreased the unspliced forms of XBP1,
confirming the validity of our assay (Fig 7A). In contrast, ceramide treatment of HepG2 cells
did not induce any significant changes in XBP1 splicing compared to solvent-treated control
cells (Fig 7A). Furthermore, ceramide did not alter the protein expression of GRP78 and
CHOP, known markers of ER stress activation, supporting the conclusion that ER stress is not
activated by ceramide in HepG2 cells (Fig 7B).
Discussion
Both inflammation and dysregulation of iron homeostasis correlate with disease severity in
NAFLD patients [5–7,61]. Since hepcidin is both an acute phase and iron-regulatory protein,
and its expression is modulated in NAFLD, it is important to understand HAMP regulation by
Fig 7. Ceramide did not induce ER stress in HepG2 cells (A) HepG2 cells, treated with 60 μMC2
ceramide and solvent (solv.) control or 10 μg/ml tunicamycin (TUNI), as positive control, for 8 hours were
used for XBP1 splicing assay, as described in the experimental procedures. (B)Whole cell lysates from
solvent (solv.) or ceramide-treated HepG2 cells were employed for western blotting to determine GRP78 and
CHOP protein expression using specific antibodies. An anti-gapdh antibody was employed as a protein
loading control.
doi:10.1371/journal.pone.0147474.g007
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different lipids. Here, we have shown a specific role for the lipid species, ceramide in the regula-
tion ofHAMP transcription via the activation of JAK/STAT3 signaling in human hepatoma
cells.
Besides actinomycin D, our promoter assays also indicated the effect of ceramide on HAMP
transcription, which was confined to a 0.6kbp promoter region proximal to the translation ini-
tiation site. The STAT3 response element, harbored within this region of HAMP promoter, has
previously been reported to mediate the transcriptional regulation of HAMP by IL-6 [15,44]. It
is however unknown whether the activation of JAK/STAT3 signaling by other stimuli such as
ceramide also exerts similar effects on HAMP transcription. Our findings in this study con-
firmed the presence of such a mechanism in human hepatoma cells. Firstly, ceramide induced
the phosphorylation of STAT3 on tyrosine 705, and its interaction withHAMP promoter in
HepG2 cells. Secondly, the mutation of this particular STAT3 response element significantly
inhibited the stimulatory effect of ceramide onHAMP promoter activity, indicating the
requirement for STAT3 binding to HAMP promoter for the activation of HAMP transcription
by ceramide. Furthermore, inhibition of STAT3 with a chemical inhibitor and siRNA signifi-
cantly decreased the stimulatory effect of ceramide on HAMP promoter activity and mRNA
expression.
Although we have established a novel role for ceramide in hepcidin regulation, it is also
important to note that this may not be entirely mediated by JAK/STAT3 signaling. Namely,
the positive effect of ceramide on hepcidin mRNA expression and promoter activity was not
completely blocked by the inhibition of JAK/STAT3 signaling. Moreover, despite the mutation
of STAT3 response element within 0.6 kbHAMP promoter, a residual activation of HAMP
promoter was still observed in ceramide-treated HepG2 cells. On the other hand, this mutation
completely reversed the effect of IL-6. These results indicate that unlike IL-6, ceramide may
not be completely dependent on STAT3 for HAMP promoter activation, and utilizes additional
signaling pathways. Accordingly, we have shown the stimulation of NF-κB and JNK phosphor-
ylation by ceramide in HepG2 cells. Similar effects were also reported in other cells [32,33,38–
40]. Despite elevated phosphorylation, our ChIP assays did not detect changes in NF-κB bind-
ing to HAMP promoter. Interestingly, ceramide weakened the basal level of c-Jun binding to
HAMP promoter. This negative effect does not involve JNK because ceramide stimulated JNK
phosphorylation in HepG2 cells. It may be due to a potential competition with STAT3 because
their response elements are in close proximity within 0.6kbHAMP promoter region (i.e. AP-1:
-125 to -134; STAT3: -135 to -143 proximal to ATG). Additionally, our results with SP600125,
which inhibited JNK phosphorylation but did not alter ceramide-induced HAMP expression,
also exclude a role for JNK/c-Jun signaling in the regulation ofHAMP transcription by
ceramide.
Aberrant lipid metabolism in animal models of obesity [62] and treatment of human cancer
cells with ceramide [55,57] have been shown to trigger ER stress. Experimental ER stress induc-
ers are known to activate HAMP transcription [58]. However, ceramide failed to induce ER
stress in HepG2 cells under our experimental conditions. Similarly, a role for ceramide was
excluded in ER stress induced by saturated fatty acids in liver cells [63]. Although NF-κB, JNK/
c-Jun or ER stress are not involved, this does not exclude a role for other pathways, which may
potentially act in synergy with JAK/STAT3 signaling to mediate the activation ofHAMP tran-
scription by ceramide in liver cells.
In summary, we have demonstrated a novel role for the biologically active lipid intermedi-
ate, ceramide in the transcriptional regulation of HAMP in human liver cells. Our findings
have also indicated that ceramide can directly activate inflammatory signaling in hepatocytes
in vitro in the absence of macrophages or cytokines. This study establishes an important link
between lipid-mediated inflammation and iron metabolism, which may have implications for
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fatty liver disease pathology and obesity. The involvement of ceramide and hepcidin in
NAFLD disease progression warrants further research.
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